Source comparison
Melanotan-1 Typically Administered in Research: Administration Comparison
Subcutaneous (standard) 0.16–0.25 mg/kg daily 2–4 hours to peak plasma 6–12 mm, 45–90° angle Long-term photoprotection studies, pigmentation response Optimal for controlled plasma kinetics and consistent bioavailability. Standard route for dermatology trials I
This comparison does not assign a generated winner or score.
- Subcutaneous (standard)
- 0.16–0.25 mg/kg daily
- 2–4 hours to peak plasma
- 6–12 mm, 45–90° angle
- Long-term photoprotection studies, pigmentation response
- Optimal for controlled plasma kinetics and consistent bioavailability. Standard route for dermatology trials
- Intramuscular
- 30–90 minutes to peak plasma
- 25–38 mm, 90° angle
- Acute dosing studies, rapid onset protocols
- Faster absorption but higher variance in plasma concentration; not recommended for multi-week protocols
- Intradermal
- 0.05–0.10 mg/kg daily
- 4–6 hours to peak plasma
- 1–3 mm, 10–15° angle
- Localised skin response studies, small volume doses
- Technically difficult, high failure rate, used only for specialised endpoint measurement
- Intravenous
- 0.16 mg/kg bolus
- 5–15 minutes to peak plasma
- Direct venous access
- Pharmacokinetic studies, bioavailability baseline
- Gold standard for PK studies but impractical for chronic dosing; requires clinical setting